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Introduction. Invasive aspergillosis (IA) is an important cause 
of morbidity and mortality in immunocompromised patients. 
During recent years, a rising incidence of IA in Intensive Care 
Unit (ICU) patients has been reported. The patterns of IA related 
infection may differ according to the type of underlying disease. 
Unfortunately little is known about the characteristics of IA in 
ICU patients. In the present study we assessed IA related clinical 
and bronchoscopy findings in ICU patients.
Materials and methods. This study was performed at the ICU 
units in Sari and Babul, Mazandaran from August 2009 through 
September 2010. We analysed 43 ICU patients with underlying 
predisposing conditions for IA. Bronchoalveolar lavage (BAL) 
samples were collected by bronchoscope twice a weekly. The 
samples were analyzed by direct microscopic examination, cul-
ture and non-culture based diagnostic methods. Patients were 
assigned a probable or possible diagnosis of IA according to the 
consensus definition of the EORTC/MSG.
Results. Out of 43 suspected patients to IA, 13 (36.1%) cases 
showed IA. According to criteria presented by EORTC/MSG, they 
were categorized as: 4 cases (30.8%) of possible IA and 9 (69.2%) 
of probable IA. The observed mortality was 69.2%. The main 
underlying predisposing conditions were neutropenia, hematologic 
malignancy, and COPD. The macroscopic finding in bronchoscopy 
included of Prulent secretion (46.6%), Mucosal bleeding (30.7%), 
Mucosal erythema (23%), Trachobronchomalasia (15.3%).
Conclusion. The diagnosis of IA in patients with critical illness in 
ICU is even more difficult. The clinical diagnostic process is often 
dependent on indirect circumstantial data enhancing the proba-
bility of IA. Bronchoscopy with inspection of the tracheobronchial 
tree, sampling of deep airway secretions and BAL can be helpful.
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Summary
Introduction
Invasive aspergillosis (IA) is a major cause of morbidity 
and mortality in immunocompromised patients receiv-
ing intensive chemotherapy, neutropenia, allogeneic 
stem cell transplantation, and solid organ transplanta-
tion [1-3]. Also intensive care unit (ICU) patients at risk 
for IA, which the specific defects in host defense mecha-
nisms that increase their risk for IA [4]. During recent 
years, a rising incidence of IA in ICU patients (ranges 
from 0.3% to as much as 5.8%) has been reported and 
it carries an overall mortality rate exceeding 80% [5-8]
This high mortality is at least partially related to diffi-
culties in timely diagnosis, caused by insensitive and 
non-specific clinical signs and lack of unequivocal di-
agnostic criteria [7]. Thus IA must be considered as an 
emerging and mortal infectious disease in ICU patients 
even in the absence of an apparent predisposing immu-
nodeficiency. The patterns of IA related infection may 
differ according to the type of underlying disease [9]. 
Unfortunately little is known about the characteristics of 
IA in ICU patients. It is often made late in the course 
of the infection because of clinical manifestations are 
usually non-specific, mycological cultures are difficult 
to interpret, and invasive procedures require to obtain 
histological specimens [10]. In Iran, there is no report on 
invasive fungal infections in ICU patients, in the present 
study we assessed IA related clinical risk factors and 
bronchoscopy findings IA in ICU patients.
Materials and methods 
This study was performed at medical ICU units in Sari 
and Babul city in Mazandaran province from August 2009 
through September 2010 all patients admitted to our were 
reviewed for inclusion in this study. We analysed ICU pa-
tients with one of the following underlying predisposing 
conditions who were at risk for developing IA; neutro-
penic patients including after chemotherapy or hemato-
logic malignancy and non neutropenic patients including 
chronic obstructive pulmonary disease (COPD), solid or-
gan transplant recipient, recipient of any other immuno-
suppressive treatment, and ICU stay more than 21 days. 
Radiological patterns of IA were classified either airway-
invasive forms or angio-invasive forms, based on previ-
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ous studies [11, 12]. Airway IA was considered when the 
predominant CT findings revealed a tree-in-bud pattern 
or peribronchial consolidation. During hospitalization, 
bronchoalveolar lavage (BAL) samples were collected 
by bronchoscope (Olympus BF20D) twice a weekly. The 
bronchus of the lobe in which consolidation was imaged 
by chest radiograph or chest CT scan was wedged, and 50 
mL of 0.9% sterile saline solution at room temperature 
was instilled with a syringe through the working chan-
nel of the bronchoscope. The total volume of saline so-
lution instilled into the lung was typically 150 mL, and 
50 to 100 mL of BAL fluid was recovered. The presence 
of any tracheal or bronchial lesions was recorded by the 
endoscopist. The BAL samples were analyzed by culture 
and non-culture based diagnostic methods. BAL galacto-
mannan (GM) antigen levels were measured by ELISA 
(Platelia Aspergillus GM EIA) assays. An optical density 
ratio of 1.0 was considered positive for GM in BAL sam-
ples [13]. 
Patients were assigned a probable or possible diagnosis of 
IA according to the consensus definition of the EORTC/
MSG [14], with the modification. Probable IA was diag-
nosed when culture or cytology analyses of BAL fluid 
tested for Aspergillus species, and when one major clini-
cal criteria (such as halo sign, air-crescent sign, or cavity 
within an area of consolidation on CT scan) or 2 minor 
clinical criteria (such as symptoms of lower respiratory 
tract infection, pleural rub, or a new infiltrate without an 
alternative diagnosis) were evident. Possible IA was de-
fined by the presence of a host factor and either a positive 
culture or 1 major (or 2 minor) criteria. In this present 
study we were not be able to define a proven IA case (his-
tologic evidence of tissue invasion) because there was an 
explicit refusal of the family to doing biopsy or autopsy.
Results
During the study period, 43 patients fulfilling the inclu-
sion criteria were enrolled. According to the EORTC/
MSG criteria, cases were classified as 9 (69.2%) of 
probable IA and 4 cases (30.8%) of possible IA. The 
median patient age was 56.5 years and 58.8% patients 
were male. The observed mortality in IA patients was 
69.2% and 4 (30.7%) had survived. The characteristics 
of patients are summarized in Table I.
We found that the incidence of fever and rate of res-
piratory failure requiring mechanical ventilation were 
significantly higher in neutropenic patients than in pa-
tients with Solid organ cancer and COPD (P < 0.001). 
The macroscopic finding in bronchoscopy included of 
Prulent secretion (46.6%), Mucosal bleeding (30.7%), 
Mucosal erythema (23%), Trachobronchomalasia 
(15.3%). As showed in Table II, mucosal bleeding and 
prulent secretion were more prevalent in patient with IA. 
Neutropenic patients were more likely to exhibit peri-
bronchial consolidation, mucosal bleeding, and mass-
like consolidation. Hence, the airway-invasive pattern 
was more commonly observed in neutropenic patients 
(85.7%) than in other patients with IA. 
Conclusions 
Although a few studies have focused on the IA in ICU pa-
tients [15, 16], evaluation incidence of IA in ICU patients 
is important. The diagnosis of IA in patients with critical 
illness in ICU is even more difficult, because of Clini-
cal manifestations are often non-specific, and diagnostic 
criteria have been adapted from standardized guidelines 
developed for ICU patients [10]. In addition, critically ill 
patients with prolonged stays in the ICU often develop 
pulmonary infiltrates, atelectasis and/or acute respira-
tory distress syndrome, whereas patients with prior lung 
disease (e.g. COPD) may present with pre-existing cavi-
ties on conventional chest radiographs [10]. In our study 
clinical signs are often lacking in ICU patients with IA, 
as reported by a previous study [8, 10, 16]. The radiolog-
ical patterns of IA are usually characterized as airway-
invasive or angio-invasive [17]. Therefore, our finding 










Age, yr., mean 47.8 62 58.4 56.5
Sex, male, (%) 6 (66.6) 2 (50) 16 (53) 24(58.8)
ICU length of stay, days 7.3 9.75 25 19.6
mechanical ventilation, days 6.7 6.25 22 18.2
No. of deaths (%) 7 (77.8) 2 (50) 8 (26.7) 16(37)
definition of abbreviations: IA= invasive aspergillosis; ICU= intensive care unit.







mucosal bleeding (%) 4 (30.7) 3 (10) 0.0154
prulent secretion (%) 6 (46.6) 1 (3.3) 0.0082
mucosal erythema (%) 3 (23) 4 (13.3) 0.0399
Tracheobronchomalasia (%) 2 (15.3) 0 0.0952
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that the airway- invasive pattern was more commonly 
observed in neutropenic patients with IA is in agree-
ment with previous reports [9, 17, 18]. Fiberoptic bron-
choscopy with inspection of the tracheobronchial tree, 
sampling of deep airway secretions and BAL can be 
helpful [16]. This technique is a useful first procedure 
for the evaluation of IA patients, but a negative result 
does not exclude aspergillosis. Our study had several 
limitations. Firstly, we had a relatively small sample 
size which may have limited our power to detect dif-
ferences between the groups. Secondly, because the 
critical condition of many patients did not permit an 
invasive diagnostic procedure and autopsy after death 
from patients suspected IA, has not been reported cases 
of proven IA.
In conclusion, the clinical and radiological features of 
IA differed between patients with underlying disease in 
ICU unit. Its occurrence in ICU usually entails a poor 
prognosis despite major recent improvements in the 
diagnosis and treatment of IA in patients with haema-
tological diseases. Multicenter studies are warranted to 
explore the exact incidence and to better delineate clini-
cal risk factors and bronchoscopy findings IA in ICU 
patients.
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